Vor Biopharma Inc. (NYSE:VOR) Receives Average Recommendation of “Moderate Buy” from Analysts

Vor Biopharma Inc. (NYSE:VOR) has been assigned a consensus recommendation of “Moderate Buy” from the nine brokerages that are currently covering the firm, MarketBeat reports. Four research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $121.3333.

A number of brokerages have recently commented on VOR. HC Wainwright reiterated a “buy” rating and set a $60.00 price objective on shares of Vor Biopharma in a research report on Thursday, August 14th. Wedbush reiterated an “outperform” rating on shares of Vor Biopharma in a research report on Thursday, June 26th.

Vor Biopharma Stock Performance

Shares of NYSE VOR opened at $27.93 on Thursday. The stock has a fifty day moving average price of $39.97 and a two-hundred day moving average price of $22.99. The firm has a market cap of $176.91 million, a P/E ratio of -16.93 and a beta of 2.05. Vor Biopharma has a 1 year low of $2.62 and a 1 year high of $65.80.

Insider Activity at Vor Biopharma

In other news, major shareholder Reprogrammed Interchange Llc sold 22,363 shares of the stock in a transaction on Tuesday, September 16th. The stock was sold at an average price of $30.80, for a total transaction of $688,780.40. Following the completion of the sale, the insider owned 1,639,060 shares in the company, valued at approximately $50,483,048. This represents a 1.35% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last three months, insiders sold 756,918 shares of company stock worth $12,573,293. 0.45% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Vor Biopharma

A number of institutional investors and hedge funds have recently modified their holdings of VOR. Northern Trust Corp lifted its holdings in shares of Vor Biopharma by 39.0% in the fourth quarter. Northern Trust Corp now owns 157,617 shares of the company’s stock valued at $175,000 after purchasing an additional 44,252 shares in the last quarter. Two Sigma Investments LP lifted its holdings in shares of Vor Biopharma by 18.9% in the fourth quarter. Two Sigma Investments LP now owns 163,064 shares of the company’s stock valued at $181,000 after purchasing an additional 25,930 shares in the last quarter. Money Concepts Capital Corp lifted its holdings in shares of Vor Biopharma by 106.1% in the first quarter. Money Concepts Capital Corp now owns 51,535 shares of the company’s stock valued at $37,000 after purchasing an additional 26,535 shares in the last quarter. OMERS ADMINISTRATION Corp purchased a new stake in shares of Vor Biopharma in the first quarter valued at $100,000. Finally, Goldman Sachs Group Inc. lifted its holdings in shares of Vor Biopharma by 218.2% in the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock valued at $61,000 after purchasing an additional 58,247 shares in the last quarter. Institutional investors and hedge funds own 97.29% of the company’s stock.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.